Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Known or Suspected Focal Liver Lesions
Conditions
Known or Suspected Focal Liver Lesions
Trial Timeline
Aug 1, 2007 → Aug 1, 2008
NCT ID
NCT00526188About Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Gadoxetic Acid Disodium (Primovist, BAY86-4873) is a phase 3 stage product being developed by Bayer for Known or Suspected Focal Liver Lesions. The current trial status is completed. This product is registered under clinical trial identifier NCT00526188. Target conditions include Known or Suspected Focal Liver Lesions.
What happened to similar drugs?
0 of 1 similar drugs in Known or Suspected Focal Liver Lesions were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00908596 | Approved | Completed |
| NCT01411449 | Pre-clinical | Completed |
| NCT00924248 | Pre-clinical | Completed |
| NCT00526188 | Phase 3 | Completed |
Competing Products
12 competing products in Known or Suspected Focal Liver Lesions
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carboplatin + Gemcitabine + Capecitabine | Eli Lilly | Phase 2 | 27 |
| Etoposide + Gemcitabine + Irinotecan + Paclitaxel + Carboplatin | Eli Lilly | Phase 3 | 40 |
| paclitaxel/carboplatin + cetuximab | Merck | Phase 2 | 31 |
| Pembrolizumab | Merck | Phase 2 | 35 |
| 177Lu-FAP-2286 | Novartis | Phase 2 | 42 |
| Oxaliplatin + Capecitabine | Roche | Phase 2 | 35 |
| Alectinib + Vismodegib + Ipatasertib + Olaparib + Erlotinib + Bevacizumab + Vemurafenib + Cobimetinib + Trastuzumab Subcutaneous (SC) + Pertuzumab + Atezolizumab + Carboplatin + Paclitaxel + Cisplatin + Gemcitabine + Entrectinib + Ivosidenib + Pemigatinib | Roche | Phase 2 | 35 |
| Sintilimab | Innovent Biologics | Phase 2 | 35 |
| Gemcitabine (Gemox) + Oxaliplatin | Sanofi | Phase 2 | 35 |
| Diosmectite (Smecta®) | Ipsen | Phase 1 | 26 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 26 |
| TD-1607 + Placebo | Theravance Biopharma | Phase 1 | 23 |